Leiden, 18 March 2026. BIMINI Biotech has been awarded funding through the Health Holland International Kickstarter Call for Public-Private Partnerships for a project advancing first-in-class therapeutics for acute myeloid leukaemia.

The €440,000 AML-WASP project brings together BIMINI Biotech as project lead, the Institute of Oncology Research in Switzerland and the Central University of Punjab in India.

Advancing a novel approach to AML

The consortium will further develop BIMINI’s proprietary small-molecule activators of Wiskott-Aldrich Syndrome Protein (WASp). The approach is designed to exploit WASp dependency in selected leukaemia cells and induce cancer-cell death through a differentiated mechanism of action.

BIMINI has identified early lead compounds with low-nanomolar activity in AML cell models and generated in vivo proof-of-concept data in AML models. AML-WASP will focus on lead optimisation, validation in relapsed and refractory AML models and identification of predictive biomarkers.

Dr. Digvijay Gahtory, CEO of BIMINI Biotech, highlighted the opportunity to combine medicinal chemistry and translational oncology expertise across Europe and India. The partners aim to generate the evidence required to move WASp-targeting therapeutics towards further preclinical and clinical development.

Project LSHI25007 is co-funded by PPP Allowance awarded by Health Holland to stimulate public-private partnerships.

About BIMINI Biotech

BIMINI Biotech is a Leiden-based preclinical biotechnology company developing first-in-class small-molecule therapeutics targeting WASp.